Cart
×
Sarepta U.S. Patient Affairs – Newsletter for the Duchenne Community
View the Sarepta Summer 2019 Newsletter HERE.
Catabasis Connection – Phase 3 PolarisDMD trial for edasalonexent
The latest edition of the Catabasis Connection newsletter discusses Phase 3 PolarisDMD trial for edasalonexent in Duchenne. Read the full newsletter here.
WAVE Open Letter to Community
WAVE Open Letter to Community
Catabasis Connection – March 2019
In the latest Catabasis Connection, they take us behind-the-scenes with the PolarisDMD experience. Learn what it’s like to participate in their PolarisDMD clinical trial. Read the full newsletter here.
The Phase 3 PolarisDMD Trial Goes Global
With a flurry of recent activity, 17 trial sites are now open for enrollment. We are especially excited to share that our first international sites in Canada and Australia have […]
Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053)
SRPT press release – golodirsen NDA acceptance 02 14 19
NS Pharma Community Letter
We are excited that our industry partner, NS Pharma, has applied for accelertated approval for it’s exon 53 skipping therapy, viltolarsen. We applaud the dedication to the Duchenne community by […]
Sarepta Therapeutics Advocacy Newsletter October 2018
Dear Duchenne Advocacy Leaders, Lately we have heard many stop to consider the progress made in the last decade in Duchenne treatment and care. Improvements have been driven by this […]